United Therapeutics Europe

Inhaled Treprostinil (OCR19684) is a small-molecule prostanoid therapy in development by United Therapeutics Europe Ltd for sarcoidosis, currently in Phase 2 clinical development. Treprostinil is an established prostacyclin analog approved globally across multiple formulations and routes of administration, with the inhaled route being investigated for pulmonary manifestations of sarcoidosis. The program completed Phase 2 as of February 2026, with clinical trial NCT03814317 providing the evidence base. The active pharmaceutical ingredient treprostinil is already approved in the European Union (EMA authorization dates 21 September 2018 and 30 July 2025) and United States (multiple NDA and ANDA approvals across manufacturers including United Therapeutics, Actavis Labs, Alembic Global, Dr Reddy's, and others). The inhaled formulation represents a route optimization strategy for pulmonary sarcoidosis, leveraging the established safety and efficacy profile of treprostinil while targeting direct lung delivery. Current regulatory status and next development milestones remain not yet disclosed.

Sarcoidosis is a multisystem inflammatory disorder with significant pulmonary involvement in a substantial proportion of patients, creating an unmet medical need for targeted pulmonary therapies. Pulmonary sarcoidosis can progress to fibrosis and respiratory compromise, limiting treatment options beyond corticosteroids and immunosuppressants. Inhaled treprostinil offers potential advantages through direct lung delivery of a vasodilatory and anti-inflammatory prostanoid, potentially improving efficacy while reducing systemic exposure compared to systemic routes. The competitive landscape for sarcoidosis therapeutics is limited, with few disease-specific approved agents, making a novel inhaled formulation strategically significant. Treprostinil's established clinical profile across multiple indications (pulmonary hypertension, interstitial lung disease) provides a foundation of safety data, potentially accelerating development and regulatory pathways. The market opportunity encompasses patients with pulmonary sarcoidosis who are refractory to or intolerant of conventional therapies. Commercial positioning benefits from United Therapeutics' existing expertise in inhaled prostanoid delivery and pulmonary disease management, supporting competitive differentiation in a relatively underserved therapeutic area.

Drug Class: Prostacyclin analog (prostanoid).

Modality: Small molecule.

Route of Administration: Inhalation.

Active Pharmaceutical Ingredient: Treprostinil (INN).

Therapeutic Classification: Blood and blood forming organs (ATC B01).

Mechanism of Action: Not disclosed in available facts; however, treprostinil is a prostacyclin analog with vasodilatory, antiplatelet, and anti-inflammatory properties.

Target: Not disclosed in available facts.

Related Therapies: Treprostinil is available in multiple formulations and routes globally, including subcutaneous, intravenous, and oral formulations approved for pulmonary hypertension and other pulmonary conditions. The inhaled route represents a formulation optimization for direct pulmonary delivery.

Regulatory Status: Treprostinil as an active ingredient is approved in the European Union (EMA product numbers EMEA/H/C/004847 and EMEA/H/C/005207; MAH SciPharm Sàrl) and in the United States (multiple NDA and ANDA approvals). The inhaled formulation for sarcoidosis is investigational.

European Union: Treprostinil (active ingredient) is approved by the European Medicines Agency under product numbers EMEA/H/C/004847 and EMEA/H/C/005207, with Marketing Authorization Holder SciPharm Sàrl. Authorization dates are 21 September 2018 and 30 July 2025. The inhaled formulation for sarcoidosis (OCR19684) is investigational.

United States: Treprostinil is approved via multiple New Drug Applications (NDA021272, NDA022387, NDA208276, NDA214324) and Abbreviated New Drug Applications (ANDA203649, ANDA206648, ANDA208906, ANDA209382, ANDA210214, ANDA211574) across multiple sponsors including United Therapeutics, Actavis Labs, Alembic Global, Dr Reddy's, PH Health, Sandoz, and Teva Pharmaceuticals USA. The inhaled formulation for sarcoidosis is investigational.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed.

Expected Loss of Exclusivity: Not yet disclosed.

Strategic Implications: United Therapeutics' development of inhaled treprostinil for sarcoidosis leverages the company's established expertise in inhaled prostanoid delivery and pulmonary disease management. The Phase 2 completion as of February 2026 positions the program for potential Phase 3 initiation or regulatory pathway decisions, though next milestones are not yet disclosed. The use of an established, globally approved active ingredient (treprostinil) with a novel route optimization (inhalation) for a new indication (sarcoidosis) represents a rational development strategy with potentially lower technical and regulatory risk compared to de novo molecular entities.

Competitive Implications: The sarcoidosis market lacks numerous approved disease-specific therapies, creating a differentiation opportunity. Treprostinil's vasodilatory and anti-inflammatory properties may address unmet needs in pulmonary sarcoidosis, particularly for patients refractory to corticosteroids or immunosuppressants. The competitive data provided does not clearly identify direct sarcoidosis competitors, suggesting limited competitive pressure in this specific indication space.

Future Catalysts: Key catalysts include Phase 3 trial initiation (if planned), interim or final efficacy and safety data readouts, regulatory interactions with FDA and EMA, and potential breakthrough therapy or fast-track designations if warranted by Phase 2 data. Publication of NCT03814317 results would provide critical evidence for program advancement.

Expected Milestones: Next development milestones are not yet disclosed. Typical progression would include Phase 3 initiation, regulatory pre-submission meetings, and potential NDA/MAA filings, though timelines remain unknown.